CDNA

SEC source: 0001217234-20-000184 · wf-form4_160227742391391.xml · nonDerivative · entry 5

King Sasha · CIK 0001721150 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,539

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001217234-20-000184 · wf-form4_160227742391391.xml · nonDerivative · entry 4

King Sasha · CIK 0001721150 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,205

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001217234-20-000184 · wf-form4_160227742391391.xml · nonDerivative · entry 3

King Sasha · CIK 0001721150 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,538

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001217234-20-000184 · wf-form4_160227742391391.xml · nonDerivative · entry 2

King Sasha · CIK 0001721150 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,427

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001217234-20-000184 · wf-form4_160227742391391.xml · nonDerivative · entry 1

King Sasha · CIK 0001721150 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,760

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001217234-20-000178 · wf-form4_160202225822357.xml · derivative · entry 3

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,340

Underlying: Common Stock · 10,000 shares

Expires 2027-10-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3 · derivative.exercise_date: 25% of the shares subject to the option vested on October 20, 2018 and 1/48th of the shares subject to the option vest monthly thereafter.

SEC source: 0001217234-20-000178 · wf-form4_160202225822357.xml · nonDerivative · entry 2

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 421,974

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.75 to $42.64, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

SEC source: 0001217234-20-000178 · wf-form4_160202225822357.xml · nonDerivative · entry 1

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 431,974

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001217234-20-000174 · wf-form4_160167830715413.xml · nonDerivative · entry 1

SNYDERMAN RALPH · CIK 0001178031 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,457

F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001217234-20-000170 · wf-form4_160167777054918.xml · nonDerivative · entry 1

COURNOYER CHRISTINE · CIK 0001180466 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,848

F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001217234-20-000176 · wf-form4_160167847918469.xml · nonDerivative · entry 1

Bickerstaff George · CIK 0001329646 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,487

F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001217234-20-000172 · wf-form4_160167821990388.xml · nonDerivative · entry 1

Goldberg Michael · CIK 0001366412 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,404

F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001217234-20-000168 · wf-form4_160167758768930.xml · derivative · entry 8

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,340

Underlying: Common Stock · 8,660 shares

Expires 2027-10-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F7 · derivative.exercise_date: 25% of the shares subject to the option vested on October 20, 2018 and 1/48th of the shares subject to the option vest monthly thereafter.

SEC source: 0001217234-20-000168 · wf-form4_160167758768930.xml · derivative · entry 7

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,340 shares

Expires 2024-11-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F5 · derivative.exercise_date: The shares subject to the option vested in three equal installments based upon the Issuer's achievement of certain performance goals as follows: (i) one third vest upon the Issuer's determination, which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the offer by the Issuer to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended, and supplemented on October 24, 2017 and November 9, 2017 (the "Exchange Offer"), (ii) one third vest upon the Issuer's determination,

F6 · derivative.exercise_date: (Continued from footnote 5) which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, and (iii) one third vest in the event the closing sales price of the Issuer's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer.

SEC source: 0001217234-20-000168 · wf-form4_160167758768930.xml · nonDerivative · entry 4

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 421,974

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.01 to $41.47, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

SEC source: 0001217234-20-000168 · wf-form4_160167758768930.xml · nonDerivative · entry 3

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 424,474

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.00 to $41.00, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

SEC source: 0001217234-20-000168 · wf-form4_160167758768930.xml · nonDerivative · entry 2

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 441,974

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001217234-20-000168 · wf-form4_160167758768930.xml · nonDerivative · entry 1

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 433,314

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001217234-20-000166 · wf-form4_160151101839714.xml · derivative · entry 5

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,340

Underlying: Common Stock · 16,992 shares

Expires 2024-11-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F4 · derivative.exercise_date: The shares subject to the option vested in three equal installments based upon the Issuer's achievement of certain performance goals as follows: (i) one third vest upon the Issuer's determination, which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the offer by the Issuer to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended, and supplemented on October 24, 2017 and November 9, 2017 (the "Exchange Offer"), (ii) one third vest upon the Issuer's determination,

F5 · derivative.exercise_date: (Continued from footnote 4) which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, and (iii) one third vest in the event the closing sales price of the Issuer's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer.

F6 · balance_after: The total reported in Column 9 has been adjusted to correct an understatement of total shares subject to the option by 23,158 shares first reflected in a Form 4 filed on April 18, 2019.

SEC source: 0001217234-20-000166 · wf-form4_160151101839714.xml · nonDerivative · entry 2

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 421,974

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.50 to $37.81, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

SEC source: 0001217234-20-000166 · wf-form4_160151101839714.xml · nonDerivative · entry 1

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 438,966

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001217234-20-000164 · wf-form4_160082364031692.xml · derivative · entry 4

Cohen Fred E · CIK 0001339358 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,745 shares

Expires 2026-07-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 1/12th of the shares subject to the option vested on August 1, 2016 and the remaining shares subject to the option vested monthly thereafter through July 1, 2017.

SEC source: 0001217234-20-000164 · wf-form4_160082364031692.xml · derivative · entry 3

Cohen Fred E · CIK 0001339358 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,679 shares

Expires 2024-11-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to the option vested in three equal installments based upon the Issuer's achievement of certain performance goals as follows: (i) one third vest upon the Issuer's determination, which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the offer by the Issuer to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended, and supplemented on October 24, 2017 and November 9, 2017 (the "Exchange Offer"), (ii) one third vest upon the Issuer's determination,

F2 · derivative.exercise_date: (Continued from Footnote 1) which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, and (iii) one third vest in the event the closing sales price of the Issuer's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer.

SEC source: 0001217234-20-000164 · wf-form4_160082364031692.xml · nonDerivative · entry 2

Cohen Fred E · CIK 0001339358 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,893

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001217234-20-000164 · wf-form4_160082364031692.xml · nonDerivative · entry 1

Cohen Fred E · CIK 0001339358 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,148

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001217234-20-000162 · wf-form4_159960154702478.xml · derivative · entry 6

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,174

Underlying: Common Stock · 10,000 shares

Expires 2024-11-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020.

F4 · derivative.exercise_date: The shares subject to the option vest in three equal installments based upon the Issuer's achievement of certain performance goals as follows: (i) one third vest upon the Issuer's determination, which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the offer by the Issuer to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended, and supplemented on October 24, 2017 and November 9, 2017 (the "Exchange Offer"), (ii) one third vest upon the Issuer's determination,

F5 · derivative.exercise_date: (Continued from footnote 3) which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, and (iii) one third vest in the event the closing sales price of the Issuer's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer.

SEC source: 0001217234-20-000162 · wf-form4_159960154702478.xml · nonDerivative · entry 3

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 421,974

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020.

SEC source: 0001217234-20-000162 · wf-form4_159960154702478.xml · nonDerivative · entry 2

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 422,074

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $31.07 to $32.06, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

SEC source: 0001217234-20-000162 · wf-form4_159960154702478.xml · nonDerivative · entry 1

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 431,974

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020.

SEC source: 0001217234-20-000154 · wf-form4_159684177791746.xml · nonDerivative · entry 1

King Sasha · CIK 0001721150 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,427

F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of vested restricted stock units.

F2 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in June 2020.

SEC source: 0001217234-20-000156 · wf-form4_159684345283899.xml · nonDerivative · entry 1

Seeto Reginald · CIK 0001688485 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,849

F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of vested restricted stock units.

F2 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in June 2020.

SEC source: 0001217234-20-000152 · wf-form4_159684032977481.xml · nonDerivative · entry 1

Bell Michael Brian · CIK 0001702824 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,277

F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of vested restricted stock units.

F2 · balance_after: These shares remain subject to a lock-up agreement entered into among the Reporting Person and the representatives of the underwriters for the Issuer's public offering of common stock completed in June 2020.

SEC source: 0001217234-20-000148 · wf-form4_159683711869207.xml · derivative · entry 9

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,281

Underlying: Common Stock · 9,848 shares

Expires 2026-01-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020.

F8 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 22, 2017 and 1/48th of the shares subject to the option vest monthly thereafter.

SEC source: 0001217234-20-000148 · wf-form4_159683711869207.xml · derivative · entry 8

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,174

Underlying: Common Stock · 3,160 shares

Expires 2024-11-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020.

F6 · derivative.exercise_date: The shares subject to the option vest in three equal installments based upon the Issuer's achievement of certain performance goals as follows: (i) one third vest upon the Issuer's determination, which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the offer by the Issuer to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended, and supplemented on October 24, 2017 and November 9, 2017 (the "Exchange Offer"), (ii) one third vest upon the Issuer's determination,

F7 · derivative.exercise_date: (Continued from footnote 6) which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, and (iii) one third vest in the event the closing sales price of the Issuer's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer.

SEC source: 0001217234-20-000148 · wf-form4_159683711869207.xml · nonDerivative · entry 5

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 421,974

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $36.7 to $37.545, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

SEC source: 0001217234-20-000148 · wf-form4_159683711869207.xml · nonDerivative · entry 4

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 428,574

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.68 to $36.615, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

SEC source: 0001217234-20-000148 · wf-form4_159683711869207.xml · nonDerivative · entry 3

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 434,382

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $34.56 to $35.16, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

SEC source: 0001217234-20-000148 · wf-form4_159683711869207.xml · nonDerivative · entry 2

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 434,982

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020.

SEC source: 0001217234-20-000148 · wf-form4_159683711869207.xml · nonDerivative · entry 1

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 425,134

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020.

SEC source: 0001217234-20-000133 · wf-form4_159417166984525.xml · derivative · entry 2

King Sasha · CIK 0001721150 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500

Underlying: Common Stock · 2,500 shares

Expires 2030-07-06

F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on July 6, 2021 and 1/48th of the shares subject to the option shall vest monthly thereafter.

SEC source: 0001217234-20-000133 · wf-form4_159417166984525.xml · nonDerivative · entry 1

King Sasha · CIK 0001721150 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,736

F1 · shares: The reported securities are represented by restricted stock units, 1/4th of which shall vest on July 6, 2021 and 1/4th of which shall vest on each anniversary thereafter.

SEC source: 0001217234-20-000137 · wf-form4_159417239691867.xml · derivative · entry 2

Seeto Reginald · CIK 0001688485 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-07-06

F3 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on July 6, 2021 and 1/48th of the shares subject to the option shall vest monthly thereafter.

SEC source: 0001217234-20-000137 · wf-form4_159417239691867.xml · nonDerivative · entry 1

Seeto Reginald · CIK 0001688485 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,262

F1 · shares: The reported securities are represented by restricted stock units, 1/4th of which shall vest on July 6, 2021 and 1/4th of which shall vest on each anniversary thereafter.

F2 · balance_after: Includes 695 shares acquired by the Reporting Person pursuant to Issuer's 2014 Employee Stock Purchase Plan.

SEC source: 0001217234-20-000135 · wf-form4_159417191098931.xml · derivative · entry 2

Bell Michael Brian · CIK 0001702824 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-07-06

F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on July 6, 2021 and 1/48th of the shares subject to the option shall vest monthly thereafter.

SEC source: 0001217234-20-000135 · wf-form4_159417191098931.xml · nonDerivative · entry 1

Bell Michael Brian · CIK 0001702824 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,896

F1 · shares: The reported securities are represented by restricted stock units, 1/4th of which shall vest on July 6, 2021 and 1/4th of which shall vest on each anniversary thereafter.

SEC source: 0001217234-20-000131 · wf-form4_159417148767668.xml · derivative · entry 11

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,129

Underlying: Common Stock · 5,240 shares

Expires 2026-01-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 22, 2017 and 1/48th of the shares subject to the option vest monthly thereafter.

SEC source: 0001217234-20-000131 · wf-form4_159417148767668.xml · derivative · entry 10

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,250

Underlying: Common Stock · 1,983 shares

Expires 2027-02-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 27, 2018 and 1/48th of the shares subject to the option vest monthly thereafter.

SEC source: 0001217234-20-000131 · wf-form4_159417148767668.xml · derivative · entry 9

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,292

Underlying: Common Stock · 2,777 shares

Expires 2027-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: 50% of the shares subject to the option vested on September 1, 2018 and 1/72nd of the shares subject to the option vest monthly thereafter.

SEC source: 0001217234-20-000131 · wf-form4_159417148767668.xml · derivative · entry 8

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-07-06

F5 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on July 6, 2021 and 1/48th of the shares subject to the option shall vest monthly thereafter.

SEC source: 0001217234-20-000131 · wf-form4_159417148767668.xml · nonDerivative · entry 5

Maag Peter · CIK 0001613855 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 421,974

F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, dated May 5, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.01 to $34.67, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.